Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on February 15, 2019, covering events occurring on February 13 and February 14, 2019. The filing addresses significant changes in executive leadership and compensation arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation.
Material Changes
- CEO Transition: Geert Cauwenbergh, Dr. Med. Sc., announced his retirement as CEO and Principal Financial Officer, effective March 1, 2019. He will remain on the Board of Directors.
- Appointment of New CEO: Gerrit Dispersyn, Dr. Med. Sc., currently President and COO, was appointed CEO and Principal Financial Officer effective March 1, 2019. He will resign as COO, and no successor COO will be appointed immediately.
- Compensation Adjustment: Dr. Dispersyn's new base salary is set at $380,000 per annum, with a performance bonus of up to 50% of base salary.
- Equity Grants: Dr. Dispersyn received 55,000 restricted stock units (RSUs) vesting over four years. He is also entitled to an additional grant of RSUs equal to 2% of outstanding common stock, subject to shareholder approval of an increase in the 2012 Long Term Incentive Plan.
- Outgoing CEO Compensation: An amendment was made to Dr. Cauwenbergh's non-plan stock compensation election, extending the vesting period for restricted shares from March 1 to June 1, 2019.
Guidance, Outlook, and Risks
The filing contains no financial guidance, revenue outlook, or discussion of market risks. Management commentary highlights Dr. Dispersyn's role in transforming the company into an immuno-oncology therapeutics firm and his leadership in finalizing clinical work in dermatology and ophthalmology programs. The transition is described as amicable, with no disagreements cited for Dr. Cauwenbergh's departure.
Investor Verification Checklist
- Verify the status of the shareholder vote required to approve the increase in shares available under the 2012 Long Term Incentive Plan for Dr. Dispersyn's 2% equity grant.
- Confirm the specific performance goals established for Dr. Dispersyn's annual bonus.
- Review the full text of the Second Amendment to Dr. Cauwenbergh's Non-Plan Stock Compensation Election (Exhibit 10.1) for detailed terms.
- Monitor the timeline for the appointment of a new Chief Operating Officer, as the Board currently has no intention to appoint one immediately.